Jounce Therapeutics, Inc. (JNCE): Price and Financial Metrics

JNCE POWR Grades

• Value is the dimension where JNCE ranks best; there it ranks ahead of 53.82% of US stocks.
• JNCE's strongest trending metric is Growth; it's been moving down over the last 179 days.
• JNCE ranks lowest in Momentum; there it ranks in the 4th percentile.

JNCE Stock Summary

• Of note is the ratio of Jounce Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 10.56% of US stocks have a lower such ratio.
• JNCE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 8.65% of US stocks.
• As for revenue growth, note that JNCE's revenue has grown -56.84% over the past 12 months; that beats the revenue growth of only 2.76% of US companies in our set.
• If you're looking for stocks that are quantitatively similar to Jounce Therapeutics Inc, a group of peers worth examining would be PLRX, GLYC, IDYA, XENE, and ATHX.
• JNCE's SEC filings can be seen here. And to visit Jounce Therapeutics Inc's official web site, go to jouncetx.com.

JNCE Valuation Summary

• In comparison to the median Healthcare stock, JNCE's EV/EBIT ratio is 133.11% lower, now standing at -9.7.
• JNCE's price/sales ratio has moved down 27.2 over the prior 56 months.
• Over the past 56 months, JNCE's price/sales ratio has gone down 27.2.

Below are key valuation metrics over time for JNCE.

JNCE Growth Metrics

Its year over year revenue growth rate is now at -53.34%.
• The year over year price growth rate now stands at 70.26%.
• Its 4 year cash and equivalents growth rate is now at 67.21%.

Over the past 15 months, JNCE's revenue has gone up $26,907,000.

The table below shows JNCE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	26.907	-83.494	-90.872
2021-09-30	89.246	-15.953	-25.167
2021-06-30	89.246	-41.276	-19.977
2021-03-31	63.878	-37.794	-43.934
2020-12-31	62.339	-27.788	-43.842
2020-09-30	0	-85.727	-101.981

JNCE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• JNCE has a Quality Grade of C, ranking ahead of 31.77% of graded US stocks.
• JNCE's asset turnover comes in at 0.314 -- ranking 144th of 682 Pharmaceutical Products stocks.
• FGEN, IDRA, and HRTX are the stocks whose asset turnover ratios are most correlated with JNCE.

The table below shows JNCE's key quality metrics over time.